At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 192 enrolled
Drug / intervention
TV005 vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Immunogenicity of the Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine Admixture TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Feb 9, 2016·Updated Jan 17, 2025
In Brief
A Phase 2 clinical trial evaluating TV005 vaccine and Placebo for Dengue. Completed, enrolled 192 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety and immunogenicity of the recombinant live attenuated tetravalent dengue virus vaccine admixture TV005 (TetraVax-DV T005) in healthy adults, adolescents, and children in Dhaka, Bangladesh.
Study Details
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartMar 2016
Primary CompletionAug 2017
Study CompletionFeb 2020
TodayJul 2026
First PostedFeb 9, 2016
Enrollment StartMar 1, 2016
Primary CompletionAug 10, 2017
Study CompletionFeb 5, 2020
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.4 years ago
Interventions
TV005 vaccinebiological
Delivered by subcutaneous injection; contains 10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31, and 10\^3 PFU of rDEN4Δ30.
Placebobiological
Delivered by subcutaneous injection